BR0107703A - Flavivìrus recombinantes e processos para uso dos mesmos - Google Patents

Flavivìrus recombinantes e processos para uso dos mesmos

Info

Publication number
BR0107703A
BR0107703A BR0107703-1A BR0107703A BR0107703A BR 0107703 A BR0107703 A BR 0107703A BR 0107703 A BR0107703 A BR 0107703A BR 0107703 A BR0107703 A BR 0107703A
Authority
BR
Brazil
Prior art keywords
recombinant
exogenous
flaviviruses
nucleic acid
processes
Prior art date
Application number
BR0107703-1A
Other languages
English (en)
Inventor
Raul Andino-Pavlovsky
Andres Mcallister-Moreno
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of BR0107703A publication Critical patent/BR0107703A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"FLAVIVìRUS RECOMBINANTES E PROCESSOS PARA USO DOS MESMOS". A presente invenção provê flavivírus recombinantes, especificamente flavivírus recombinantes que compreendem seq³ências de nucleosídeo exógenos que codificam seq³ências de aminoácido exógenos. Estes vírus de flavivírus recombinantes compreendem um ácido nucléico exógeno. A infecção de uma célula hospedeira com um flavivírus recombinante provê expressão do ácido nucléico exógeno em uma célula hospedeira e produção de um polipetídeo antigênico codificado pelo ácido nucléico exógeno. Tais flavivírus recombinantes são úteis na promoção de uma resposta imune para o polipeptídeo exógeno.
BR0107703-1A 2000-01-21 2001-01-19 Flavivìrus recombinantes e processos para uso dos mesmos BR0107703A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17744900P 2000-01-21 2000-01-21
US09/653,754 US6589531B1 (en) 2000-01-21 2000-09-01 Recombinant yellow fever virus and method of use thereof
PCT/US2001/001866 WO2001053467A1 (en) 2000-01-21 2001-01-19 Recombinant flaviviruses and methods of use thereof

Publications (1)

Publication Number Publication Date
BR0107703A true BR0107703A (pt) 2002-10-15

Family

ID=26873305

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0107703-1A BR0107703A (pt) 2000-01-21 2001-01-19 Flavivìrus recombinantes e processos para uso dos mesmos

Country Status (9)

Country Link
US (2) US6589531B1 (pt)
EP (1) EP1250421A1 (pt)
JP (1) JP2003520597A (pt)
CN (1) CN1398297A (pt)
AU (1) AU2965601A (pt)
BR (1) BR0107703A (pt)
CA (1) CA2395855A1 (pt)
MX (1) MXPA02006888A (pt)
WO (1) WO2001053467A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589531B1 (en) * 2000-01-21 2003-07-08 The Regents Of The University Of California Recombinant yellow fever virus and method of use thereof
WO2001090384A1 (en) * 2000-05-19 2001-11-29 The Board Of Trustees Of The Leland Stanford Junior University Viral vectors useful in induction of humoral or cellular immunity
EP1281767A3 (en) * 2001-07-31 2003-05-28 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of tumors
US20040120964A1 (en) * 2001-10-29 2004-06-24 Mikszta John A. Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
JP2005510244A (ja) * 2001-11-26 2005-04-21 ザ・ユニヴァーシティ・オヴ・クイーンズランド フラビウイルスワクチン送達系
EP1369491A1 (en) * 2002-06-05 2003-12-10 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
US20030228261A1 (en) * 2002-06-05 2003-12-11 Aladar Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
WO2004072274A1 (fr) * 2003-01-30 2004-08-26 Shanghai Tengen Biomedical Co., Ltd. Vaccin a base de pseudoparticules virales ayant comme support un replicon de recombinaison du virus de la dengue
EP1526185B1 (en) * 2003-10-22 2012-09-12 Genelux Corporation Use of a microorganism or cell to induce autoimmunization of an organism against a tumor
CN100562570C (zh) * 2003-06-18 2009-11-25 吉恩勒克斯公司 修饰的重组痘苗病毒及其它微生物,及其应用
CN1304579C (zh) * 2003-07-21 2007-03-14 上海天甲生物医药有限公司 重组的以黄热病病毒为载体的疫苗
WO2005040390A1 (fr) * 2003-07-21 2005-05-06 Shanghai Tengen Biomedical Co., Ltd. Vaccin recombine utilisant le virus de la fievre jaune comme vecteur
DE60329594D1 (de) 2003-08-14 2009-11-19 Genelux Corp Methode zur Herstellung eines Polypeptides, einer RNA oder einer anderen Verbindung in Tumorgewebe
BRPI0504945B8 (pt) 2005-10-31 2022-08-02 Fundacao Oswaldo Cruz Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos.
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
WO2008100292A2 (en) 2006-10-16 2008-08-21 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
EP2086581B1 (en) 2006-11-07 2014-08-13 Sanofi Pasteur Biologics, LLC Stabilization of vaccines by lyophilization
US20090081639A1 (en) * 2007-05-31 2009-03-26 Phil Hill Assay for sensitivity to chemotherapeutic agents
CA2768997C (en) 2009-07-31 2017-09-12 Xcellerex, Inc. High yield yellow fever virus strain with increased propagation in cells
CA2836299A1 (en) 2011-04-15 2012-10-18 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
CA2836501A1 (en) 2011-07-12 2013-01-17 Gwong-Jen J. Chang Identification of a west nile virus cd4 t cell epitope and use thereof
WO2013138522A2 (en) 2012-03-16 2013-09-19 Genelux Corporation Methods for assessing effectiveness and monitoring oncolytic virus treatment
WO2013158265A1 (en) 2012-04-20 2013-10-24 Genelux Corporation Imaging methods for oncolytic virus therapy
WO2014055960A1 (en) 2012-10-05 2014-04-10 Genelux Corporation Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
US11459619B2 (en) 2016-02-08 2022-10-04 The Johns Hopkins University Handheld nucleic acid-based assay for rapid identification
BR112020018188A2 (pt) * 2018-03-08 2021-02-02 Codagenix Inc. flavivírus atenuados
BR112021022733A2 (pt) * 2019-05-15 2022-02-01 Codagenix Inc Vírus da febre amarela atenuado e usos dos mesmos para o tratamento do câncer
CN110859968A (zh) * 2019-11-21 2020-03-06 四川安可康生物医药有限公司 激活对肿瘤的系统免疫反应的基因生物药物
US20240033347A1 (en) 2022-07-08 2024-02-01 Viromissile, Inc. Oncolytic vaccinia viruses and recombinant viruses and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
ES2153223T3 (es) 1991-09-19 2001-02-16 Us Health Flavivirus quimericos y/o flavivirus de crecimiento restringido.
US5965124A (en) 1991-12-06 1999-10-12 Whitehead Institute For Biomedical Research Replication-competent recombinant viral vaccines and method of producing same
DE19521705C2 (de) 1995-06-14 1997-10-09 Immuno Ag Immunogenes Konstrukt, Verfahren zu dessen Herstellung und Verwendung als Vakzine
ATE297757T1 (de) 1997-02-28 2005-07-15 Acambis Inc Chimäre impfstoffe gegen flaviviren
JP2002500003A (ja) 1997-11-28 2002-01-08 ザ・クラウン・イン・ザ・ライト・オヴ・ザ・クイーンズランド・デパートメント・オヴ・ヘルス フラビウイルスの発現および送達のシステム
US6589531B1 (en) * 2000-01-21 2003-07-08 The Regents Of The University Of California Recombinant yellow fever virus and method of use thereof

Also Published As

Publication number Publication date
WO2001053467A1 (en) 2001-07-26
US6589531B1 (en) 2003-07-08
CN1398297A (zh) 2003-02-19
MXPA02006888A (es) 2004-08-12
AU2965601A (en) 2001-07-31
US20030157128A1 (en) 2003-08-21
EP1250421A1 (en) 2002-10-23
JP2003520597A (ja) 2003-07-08
US6893643B2 (en) 2005-05-17
CA2395855A1 (en) 2001-07-26

Similar Documents

Publication Publication Date Title
BR0107703A (pt) Flavivìrus recombinantes e processos para uso dos mesmos
BRPI0412799A (pt) imunógeno, composição, ácido nucleico, célula recombinante, métodos para preparar um polipeptìdeo, para induzir um a resposta imune protetora em um paciente e para induzir uma resposta anamnésica em um paciente, e, seqüência de ácido nucleico otimizada de levedura
DK289688D0 (da) Ekspression af proapolipoprotein a-i.
ES2059565T3 (es) Virus mva de la vacuna, recombinante.
ES2527411T3 (es) Gen que confiere resistencia a Phytophthora infestans (tizón tardío) en solanáceas
DK0561890T3 (da) DNA ekspressionssystemer baseret på alphavira
DE69922958D1 (de) Hcv hüllproteine partikel : verwendung für therapeutische impfung
AR049177A1 (es) Polipeptidos y conjugados de interferon-alfa
BR7908410A (pt) Meio para deteccao de anticorpos de vhb no soro do sangue,e processo para deteccao da presenca da infeccao por virus da hepatite b em seres humanos
DE69206301D1 (de) Protein mit der Aktivität vom Typ von Cytokin, dafür kodierende rekombinante DNS, transformierte Zellen und Mikroorganismen.
ECSP066495A (es) Composiciones y metodos para inhibir la infección por virus de síndrome de punto blanco (wssv)
BRPI0411363A (pt) seqüências de ácidos nucléicos codificando e composições compreendendo peptìdeo sinal ige e/ou il-15 e processos para uso das mesmas
NO944245L (no) Rekombinante DNA-molekyler som koder for aminopeptidase-enzymer og deres anvendelse ved fremstilling av vaksiner mot helmintinfeksjoner
EA200401504A1 (ru) Слитый белок из числа регуляторных/вспомогательных белков вич
BR0012919A (pt) Vacina para uso na profilaxia e/ou no tratamento da sìndrome de ponto branco (white spot syndrome) em crustáceos, proteìna estrutural derivada do vìrus da sìndrome de ponto branco, sequência de ácido nucléico, uso de uma proteìna estrutural, composição farmacêutica, anticorpos, vacina ou formulação farmacêutica, e, kit diagnóstico para detecção de wssv
DK0851926T3 (da) Varianter af humant rekombinant gamminterferon (rhu-IFN-gamma) med forøget termisk stabilitet
DE60039677D1 (de) Akt-3 nukleinsäure, polypeptide und deren verwendung
FI961202A (fi) Grb3-3-geeni, sen variantteja ja niiden käyttöjä
DK1219301T3 (da) Vacciner, som indeholder hybridpolypeptider, der består af mindst to forskellige allergene proteiner
BR112022026248A2 (pt) Conjugados de citocinas
DE60235985D1 (de) Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk)
ATE166390T1 (de) Anti-katze immundefiziensvirus (fiv) impfstoffe
DK312787A (da) Polypeptider, fremgangsmaade til deres fremstilling, dna som koder for polypeptiderne, vektorer indeholdende saadanne gensekvenser og laegemidler indeholdende polypeptiderne
ATE381351T1 (de) Anwendung des herpes simplex virus glykoproteins- d zur unterdrückung von immunantworten
ATE403007T1 (de) Rekombinantes mva mit der fähigkeit zur expression von hcv struktur-antigenen

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]